This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
The list of questions should be getting shorter as we enter the pandemic's third year, but that isn't the case. There's another question to add to that list: is the U.S. doing enough to track the virus and its variants? Lawrence Gostin, faculty director of the O'Neill Institute for national and global health law at Georgetown University, joins Cheddar News.
As we prepare to ring in the new year, COVID cases are hitting an all-time high. Dr. Anthony Fauci has said the safest way to celebrate would be a small gathering with vaccinated family members only... far from the large, flashy parties from a few years ago. Dr. Christina Johns, senior medical advisor at PM Pediatrics, joins Cheddar News to discuss how to celebrate safely.
Jurors in the trial against Theranos CEO Elizabeth Holmes have entered day six of deliberations. Holmes is accused of lying to investors about the functionality of a newly developed blood-testing technology. Andrew George, partner at Baker Botts, joined Cheddar to break down key points in the case and what the jury might be considering during their deliberations. He also noted that the rest of Silicon Valley, including Holmes' business partner, Ramesh "Sunny" Balwani, who is facing identical charges, is closely watching the outcome of deliberations — as it could set the tone for future regulations and Balwani's own trial.
According to researchers, the state of California's cap-and-trade program is currently being undermined by forest fires caused primarily by climate change. Over the past few years, trees that were set aside for the program have been releasing carbon as they continue to burn in fires. Climate Researcher and Policy Director at CarbonPlan Danny Cullenward, joined Cheddar to discuss more.
The CDC's latest update to its COVID-19 quarantine guidelines reduces the isolation period from ten days to just five for people who test positive but are asymptomatic. Dr. Bayo Curry-Winchell, regional clinical director at Carbon Health, spoke to Cheddar's Baker Machado about the new guidance. She noted that while the reduced quarantine time "makes sense," the CDC should also require that a person test negative after their quarantine and before interacting with the public. "There is science behind it. We know that the majority of illness happens, or transmission, one to two days before the onset of symptoms and then two to three days as you have symptoms. So there is science behind the reducement of the actual five days," she said.
